Skip to main content

View full-text article in PMC

. 2012 May 29;15(4):569–580. doi: 10.1007/s10456-012-9281-1

Table 1.

Biodistribution of ⁶⁴Cu-cyclam-RAFT-c(-RGDfK-)₄ in HuH-7 tumor-bearing mice treated with TSU-68 or vehicle after 14 days of therapy

Organ	Vehicle (n = 5)	TSU-68 (n = 5)
Blood	0.07 ± 0.01	0.05 ± 0.01^a
Heart	0.59 ± 0.08	0.37 ± 0.06^a
Lung	1.58 ± 0.24	1.08 ± 0.21^a
Liver	5.37 ± 0.36	3.75 ± 0.46^a
Pancreas	0.61 ± 0.13	0.55 ± 0.15
Spleen	2.86 ± 0.49	1.65 ± 0.21^a
Stomach	1.94 ± 0.34	1.40 ± 0.19^a
Intestine	1.58 ± 0.14	0.96 ± 0.15^a
Kidney	25.4 ± 3.48	16.5 ± 3.36^a
Skin	2.21 ± 0.22	1.51 ± 0.28^a
Muscle	0.31 ± 0.07	0.21 ± 0.03^a
Bone	0.81 ± 0.23	0.47 ± 0.06^a
Tumor	2.44 ± 0.93	1.57 ± 0.53^a

Tissue radioactivity was assessed 3 h after injection of 0.74 MBq of the tracer and is expressed as % ID/g (mean ± SD)

^a P < 0.05 versus the vehicle-treated group